Research programme: MIF inhibitors - Debiopharm/Yale

Drug Profile

Research programme: MIF inhibitors - Debiopharm/Yale

Alternative Names: Macrophage Migration Inhibitory Factor inhibitors

Latest Information Update: 12 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Debiopharm Group
  • Developer Debiopharm Group; Yale University
  • Class Small molecules
  • Mechanism of Action Macrophage migration inhibitory factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 06 May 2014 Early research in Autoimmune disorders in USA (unspecified route)
  • 06 May 2014 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top